HOME

健康・医学 RESULTS

First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial -

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial - The Lancet

Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data - JTO Clinical and Research Reports

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC | New England Journal of Medicine

商品説明・詳細
送料・お届け

商品情報

First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial -,IMbrave150 efficacy results: Coprimary endpoints | TECENTRIQ® (atezolizumab),Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial - The Lancet,Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data - JTO Clinical and Research Reports,Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC | New England Journal of Medicine

残り 1 点 9150円

（4 ポイント還元！）

翌日お届け可（営業日のみ） ※一部地域を除く

お届け日: 05月02日〜指定可お届け日: (明日12:00のご注文まで)

ラッピング

対応決済方法

クレジットカード
コンビニ前払い決済
代金引換: 商品到着と引き換えにお支払いいただけます。 (送料を含む合計金額が￥299,000 まで対応可能)
ペイジー前払い決済(ATM/ネットバンキング): 以下の金融機関のATM/ネットバンクからお支払い頂けます
みずほ銀行、三菱ＵＦＪ銀行、三井住友銀行
りそな銀行、ゆうちょ銀行、各地方銀行
Amazon Pay(Amazonアカウントでお支払い)